Cargando…
Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS
Allogeneic stem-cell transplant allows for the delivery of curative graft-versus-leukemia (GVL) in patients with acute myeloid leukemia/myelodysplasia (AML/MDS). Surveillance of T-cell chimerism, measurable residual disease (MRD) and blast HLA-DR expression may inform whether GVL effectiveness is re...
Autores principales: | Loke, Justin, McCarthy, Nicholas, Jackson, Aimee, Siddique, Shamyla, Hodgkinson, Andrea, Mason, John, Crawley, Charles, Gilleece, Maria, Peniket, Andrew, Protheroe, Rachel, Salim, Rahuman, Tholouli, Eleni, Wilson, Keith, Andrew, Georgia, Dillon, Richard, Khan, Naeem, Potter, Victoria, Krishnamurthy, Pramila, Craddock, Charles, Freeman, Sylvie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365943/ https://www.ncbi.nlm.nih.gov/pubmed/37058448 http://dx.doi.org/10.1182/bloodadvances.2022009493 |
Ejemplares similares
-
Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML
por: Bennett, Joshua, et al.
Publicado: (2023) -
Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023) -
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
por: Weinberg, Olga K., et al.
Publicado: (2022) -
Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly “promising”?
por: Brunner, Andrew M., et al.
Publicado: (2022) -
Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy
por: Schnegg-Kaufmann, Annatina S., et al.
Publicado: (2023)